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Abstract
Cerebral Palsy (CP) is a limiting deficiency, characterized by a permanent 
neuromotor disorder which affects movements, resulting in non-progressive lesions 
of the immature brain during the neuro psychomotor stages. Epidemiological stud-
ies of premature births correlated with the presence of high levels of inflammation 
in the umbilical cord, amniotic fluid, and fetal blood, being that one of the most 
relevant underlying physiopathological mechanisms includes inflammation and 
intra-amniotic infection, with inflammatory response and damage to the develop-
ing brain. Recently attributed to the excessive production of cytokines, CP inflam-
mation is mostly modulated through diet restriction, intestinal dysfunction, and 
drug intake. The high prevalence of convulsive crises in individuals with CP (77%) 
on its own does not bring about post inflammatory and post convulsive cytokine 
synthesis, treated with antiepileptic medication. In these individuals, there is high 
incidence of intestinal constipation (47%), besides oral dysbiosis, gingival bleed-
ing and even greater increase in chronic inflammation. The dysbiosis causes an 
increase in mucous permeability (leaky-gut) of the gut-brain axis, and increase in 
seric endotoxin, demonstrating a persistent inflammatory state, and supporting the 
emergence of new side effects, which can become the object of future research.
Keywords: cerebral palsy, brain injury, neuroinflammation, inflammation, 
cytokines, constipation, antiepileptic drugs
1. Introduction
Cerebral Palsy (CP) covers a group of disorders in the relative development of 
movement and posture, causing limitation in task execution, attributed to non 
progressive disturbances of the central nervous system (CNS), occurring during 
fetal development or in the immature brain. It is the most common cause of physical 
incapacitation in childhood [1–3].
Motor disturbance is the fundamental alteration caused by CP and must be present. 
However, other multiple comorbidities are observed such as intellectual deficit, learn-
ing difficulties, communication problems (language disturbances, delay in speaking), 
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ophthalmic (strabismus, visual deficit), otorhinolaryngological, (hearing deficit, 
mouth breathing), pneumological (recurrent pneumonias), gastroenterological 
(oropharyngeal dysphagia, gastroesophageal reflux), nutritional (diet, deglutition), 
neurological (epilepsy, hydrocephalus), orthopedic (limbs, spine deformity, osteopo-
rosis), behavioral disturbances and proprioception (disturbances in sensorial integra-
tion) and impact on the secondary musculoskeletal, constipation and epilepsy Figure 1 
[1]. Although the structural damage to the immature brain is static and permanent, 
the consequences vary and can of change during the child’s growth and development 
through physical rehabilitation and assisted individualized therapy [1].
The estimated prevalence of CP varies from 2.3 to 2.9 per 1000 live births in the 
United States. (National Infant Health Research 2011–2013) Figure 1 [4]. About 
80% of the causes of CP are attributed to intrauterine events such as inflammations, 
congenital infections, reduced oxygen delivery, and encephalic strokes [5]. The 
remaining 20% are due to occurrences at birth, such as peripartum suffocation, low 
birth weight, acute maternal viral infections during pregnancy and postnatal and 
early childhood factors caused by accidental and non accidental traumas, hypoxia, 
and infections like meningitis [5–7].
Individuals with CP can be classified according to the most dominant clinical 
characteristic [3]:
• Dyskinetic: the lesions are located in groups of neurons at the base of the brain 
and present atypical movements, which are more evident when the individual 
makes a voluntary movement [8].
• Ataxic: caused by a dysfunction in the cerebellum, presents generalized 
 hypotonia with a loss of muscular coordination, characterized by abnormal 
force, rhythm and control or precision of movement [8].
Figure 1. 
Characteristics that accompany the subject’s life with Cerebral Palsy. (Figures Source: Adobe stock).
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• Spastic: presents hypertonia, hyperreflexia, clonus, and signs of inadequate 
coordination, and insufficient selective muscular control. The spasticity causes 
a reduction in the joint movement, secondary contractions, bone deformity, 
joint dislocations, and chronic pain. The conditions of spasticity must also be 
classified according to the anatomical distribution: unilateral (monoplegic 
and hemiplegic) and bilateral (diplegic, triplegic, quadri/tetraplegic and with 
double hemiplegia) [8].
The deambulation classification form is based on the Gross Motor Function 
Classification System, which is widely and internationally used, categorizing indi-
viduals with CP in one of five levels based on functional mobility or limitations in 
activity: Level I (walking without limitations), Level II (walking with limitations), 
Level III (walking using a hand-held mobility device), Level IV (self-mobility with 
limitations) and Level V (transported in a wheelchair) [9].
Even though CP has diverse etiology, in the center of the disease’s development, 
the effect of the inflammation regulates CP’s clinical phenotypes.
2. Inflammation early in life
Intrauterine inflammation is observed in approximately 20% of all pregnan-
cies and a surprising 85% of premature child-birth and is associated with a series 
of neurodevelopment disturbances [10]. Maternal respiratory and genitourinary 
infections which occur during prenatal hospitalizations and at the moment of birth, 
emphasize the role of the maternal inflammatory medium in CP’s pathogenesis, 
even though one should not discard an additional causal path involving hypoxemia 
in the scenario of respiratory infections. Intrauterine infections, extra-uterine 
infections, and maternal extra-amniotics diagnosed in the hospital during a 
pregnancy are also associated with a moderately increased risk of pathology in the 
child [11].
Epidemiological studies of premature births correlate the presence of high levels 
of inflammatories in the umbilical cord, amniotic liquid and fetal blood with white 
matter injury, CP and damaged development. In truth, premature babies are born in 
a serious state of inflammation [12–14].
When there is an association between inflammation and infection, premature 
delivery may be initiated with ramification of the corona amniotic membranes 
to the amniotic liquid, resulting in systemic fetal inflammation, which can affect 
several organs, including the brain. Mothers in premature labor display elevated 
concentrations of Interleukin (IL)-6 and IL-8 in the amniotic liquid [12]. The most 
commonly found cytokines were: Tumor necrosis factor alpha (TNF-α), Interferon 
(IFN)-gamma, IL-1, IL-6 and IL-18 and the imbalance in these cytokines in the 
beginning of development can have deep and long-term impact on several illnesses, 
such as CP. These alterations can occur starting in the intrauterine life to early 
infancy. The cytokines probably exert their effects, and may include modula-
tion of other immunological mechanisms [15]. These cytokines coordinate the 
host’s immune response and mediate normal signalling between immune and non 
immune cells, including in the CNS [16]. Pro-inflammatory cytokine induction in 
the maternal infectious process or in the beginning of life demonstrated an adverse 
effect on neurodevelopment [17]. While certain cytokines are considered pro or 
anti-inflammatory, certain types may exhibit both properties in different situations 
[17]. Strategies must be elaborated to inhibit the imbalance effect of cytokines as 
a therapeutic way of preventing or treating neurological diseases [15]. Recently, 
attributed to deregulated production of cytokines, CP inflammation is mainly 
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modulated through dietary restrictions, intestinal dysfunction, and medication 
intake. Convulsions alone stimulate the pro-inflammatory and pro-convulsive 
cytokine synthesis in epileptic individuals [18].
3. Epilepsy
Epilepsy is a chronic cerebral disease characterized by recurrent unprovoked 
epileptic crises [19] of diverse etiology with consequences for the neurobiological, 
cognitive, psychological, and social planes/plans, negatively impacting the affected 
individual’s quality of life [20, 21].
In the history of epilepsy there are accounts that in the neolithic period 
(Historical Period of Polished Stone X Millennium a. C.) trepanations were per-
formed in skulls in order to free the bad spirits. Skulls scarred from these interven-
tions were found in Egypt, Greece, Rome, the Orient, Equatorial Africa, in Mayan, 
Aztec and Brazilian indians, with curative objectives. In ancient Rome people with 
epilepsy were avoided for fear of contagion of the illness, and in the Middle Ages, 
they were pursued as witches [22].
In 1494, Malleus maleficarum, the witch hunting manual written by dominican 
priests linked to the Catholic Inquisition, was published. In this treatise, epileptic 
crises were a characteristic of witchcraft [23, 24]. This treatise’s orientation led to 
the the persecution, torture, and death of more than 100.000 women, being that 
the majority were epileptics [23, 24].
Worldwide prevalence of active epilepsy is estimated around .5% to 1.0% of 
the population. The prevalence of epilepsy differs among ages, sex, ethnic groups, 
and socioeconomic factors [25]. The incidence of epilepsy adjusted for age in North 
America varies between 16 in 100,000 and 51 in 100,000 people per year. The 
adjusted prevalence by age varies from 2.2 in 1000 to 41 in 1000, depending on the 
country.
Partial epilepsy may constitute up to two thirds of incident epilepsies. The 
incidence increases in populations of lower socioeconomic status [25]. It is esti-
mated that near 25–30% of the recently started crises are provoked or secondary to 
another cause. The incidence of epilepsy is higher in younger groups and continu-
ally increases after 50. The most common cause of convulsions and epilepsy in 
seniors is cerebrovascular disease [25, 26].
Among epilepsy’s etiological factors, those that stand out are: electrolytic 
(hypoglycemia, hyponatremia, hypernatremia, hypocalcemia, use of drugs like 
Teofilina, Aminofilina, antidepressants, Ciclosporina, Cocaine, Crack, amphet-
amines, Lidocaine); acute toxic effects (antidepressants, sympathomimetics, oth-
ers); irregular intake of prescribed antiepileptic medicine; Sepse, infections in the 
CNS; hypoxic cerebral lesions; cranial traumatism; ischemic or hemorrhagic stroke; 
inflammatory neoplasma (lupus cerebritis); fever and sleep deprivation [27].
Epilepsies can be classified according to the axes: topographic and etiologi-
cal. On the topographic axis, generalized epilepsies occur that are manifested by 
epileptic seizures that start in both hemispheres simultaneously. In general, they are 
genetically determined and accompanied by altered consciousness; when present, 
motor manifestations are always bilateral. Absence seizures, myoclonic seizures and 
generalized tonic–clonic seizures (GTC) are its main examples [28].
In focal epilepsies, the epileptic crises begin locally in a specific area in the brain, 
and their clinical manifestations depend on the starting point and the speed of 
the spread of the epileptogenic discharge. The crises are divided into simple focals 
(without affecting consciousness) and complex focals (at least partially affecting 
consciousness during the episode). Finally, a focal crisis, be it simple or complex, 
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when propagated throughout the cerebral cortex, can end up in a GTC, and 
 denominated a secondarily generalized focal crisis [29].
The symptomatic convulsions occur during the course of many clinical and 
neurological diseases, are generally self limited and do not persist if the subjacent 
disturbance is corrected. There may occur a reaction in the brain to physiological 
stress like sleep deprivation, fever, and abstinence from alcohol or other drugs 
such as sedatives. Other causes of symptomatic convulsions are hypertensive 
encephalopathy, renal insufficiency, sickle cell anemia, idiopathic thrombocyto-
penic purpura, systemic lupus, erythematosus, meningitis, encephalitis, traumatic 
brain injury and stroke. In these situations the cerebral function is temporarily 
 compromised [21].
It must be pointed out, regarding characteristics of symptomatic convulsions, 
that fever is the most common cause of convulsions in children between six months 
and four years of age, with 30% chance of another convulsion, increasing the risk of 
subsequent epilepsy, though not associated, and do not cause intellectual deficit [21].
The objective of epilepsy treatment is to provide the best quality of life possible 
for the person with epilepsy, through adequate control of crises, and a minimum 
of adverse effects. Seventy percent of people that have epilepsy take control of the 
crises with the appropriate use of anticonvulsant medicine [30].
Epilepsy is one of the most common comorbidities associated with motor 
damage in individuals with CP, and affects close to 77% of that population [30]. 
Clinical treatment for epilepsy is based on long term antiepileptic drug therapy 
which reduces the frequency of crises, raising the threshold of motor neurons in 
the cortex, reducing abnormal electrical discharges of the brain and limiting the 
dissemination of the excitement of the abnormal foci [29].
The antiepileptic pharmaceuticals act through different mechanisms which may 
or may not be favorable for the treatment [31]. The antiepileptic pharmaceuticals 
act through one or several mechanisms such as increasing gabaergic inhibition, 
blocking sodium channels, blocking calcium channels or connecting to protein 
SV2A of the synaptic vesicle [32].
Regarding gamma-aminobutyric acid, (GABA) it was possible to identify 
specific benzodiazepine receptors in the CNS structures, principally in the limbic 
system, allowing the comprehension of the action mechanism of these medica-
tions. By connecting to these receptors, the benzodiazepines facilitate GABA’s 
action, which is the primary inhibitory neurotransmitter of the CNS. The specific 
activation of GABA receptors induces the opening of chloride channels in the 
neuron membrane, amplifying the influx of this anion into the cell, which results 
in decreased excitability and the spread of excitatory impulses. Among the effects 
observed for these drugs are described the reduction of salivary flow, the vomiting 
reflex and the relaxation of skeletal muscles [33].
Voltage-dependent Na + is one of the principal channels responsible for the 
rapid depolarization of the widely and disorganized presence and neuronal mem-
brane in the epileptic processes [34]. These channels represent the important site 
of connection for several antiepileptic drugs such as hydantoin, carbamazepine, 
valproic acid, lamotrigine, among others [33].
The first evidence of the possible participation of channels Ca + 2 dependent on 
voltage in epilepsies came from the verification that the accentuated reductions in 
extracellular concentration of this ion can create epileptic activity in cerebral tissue 
such as the dentate gyrus and other hippocampal structures. It is known that the 
acute increase in Ca + 2 influx is important to maintain the reflex hyperexcitability, 
which occurs in convulsive processes. In this context, the Ca + 2 channels depen-
dent on voltage have an important role in the functional processes of the nervous 
system. For example, the presynaptic Ca + 2 entry is associated with the liberation 
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of these neurotransmitters and to their postsynaptic entry with sustained neuron 
depolarization. Blocking the Ca + 2 channels can produce several effects on the 
neuronal functioning: (a) blocking Type T channels (associated to absence crisis 
treatment); (b) blocking type L channels (associated with partial crisis treatment); 
(c) blocking Ca + 2 channels can prevent the liberation of excitatory neurotransmit-
ters such as glutamate and (d) blocking these channels reduces the concentration 
of Ca + 2 ions in the neuronal cytoplasm, reducing the possibility of excitotoxic 
cellular damage [33].
The first study, which evaluated the association between intestinal constipa-
tion, use of antiepileptic drugs (AEDs), and gingivitis in subjects with spastic CP, 
was published by our work group (Figure 2) [35]. It was clearly demonstrated an 
association between intestinal constipation and the use of GABA antiepileptic drugs 
(phenobarbital, primidone, benzodiazepines including diazepam, lorazepam, 
and clonazepam; topiramate, felbamate, ezogabine); GABA transporter tiagabine 
GABA transaminase (vigabatrin); synaptic release machinery SV2A (levetiracetam, 
brivaracetam α2δ gabapentin, gabapentin enacarbil, pregabalin).
Figure 2. 
Gingival bleeding and medication type: bleeding is measured by the percentage of teeth which bled after 
periodontal probing. Each kernel density estimation plot shows clustering by the type of medication taken by 
subjects. (A) Green figure show constipated subjects; (B) blue figure show non-constipated subjects; (C) Green-
to-Blue figure show the full population.
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It was described that the use of AEDs should be considered as a causal factor of 
constipation in CP subjects. A wide range of AEDs has been used either in the form 
of monotherapy or polytherapy for seizure control. Monotherapy has the advantage 
of lowering the potency of toxicity and side effects. Nevertheless, polytherapy may 
be recommended for the most neurologically compromised, despite its greater side 
effects and toxicity to the users of this treatment modality. GABA is localized in the 
gastrointestinal tract and is present in enteric nerves [35].
Regarding those people with epilepsy, it is necessary to emphasize the caution 
needed in the occurrence of a GTC in an odontological office. It characteristically 
occurs in two phases: Initially there is loss of consciousness followed by muscular 
convulsions. The steps to be taken are to immediately stop the odontological 
procedure, position the patient in lateral decubitus, and activate the medical 
emergency system.
Another situation to be observed is the possibility of leukopenia and thrombo-
cytopenia induced by antiepileptic drugs such as phenytoin, carbamazepine, and 
valproic acid, requiring the request for additional tests (blood count).
Another prevalent condition refers to drug-induced gingival overgrowth, 
also referred to as drug-induced gingival enlargement, and previously known 
as drug-induced gingival hyperplasia, is a side-effect of certain drugs where the 
gingival tissue is not the intended target organ. The key offending drug classes are 
anticonvulsants, immunosuppressants, and calcium channel blockers [36]. Gingival 
overgrowth impedes proper dental hygiene and, apart from the cosmetic damage, 
causes painful chewing and eating. Therefore, patient education and information 
about the condition and its management are essential.
4. Gut-brain axis
The gut-brain axis is an information exchange platform which allows bidirec-
tional communication between the host’s intestine and nervous system. The infor-
mation can be exchanged through a neural network, hormones, and immunological 
system [37].
The enteric nervous system consists of approximately 200 million neurons 
which control the entire digestive tract. It is composed of a web of intrinsic nerve 
fibres and ganglia, the myenteric and the submucous plexus. The myenteric plexus 
mainly controls motility of the digestive tract (peristalsis) and is located deep 
between the longitudinal and the circular layers of the entire digestive tract. It 
is mainly composed by a network of ganglia connected by unmyelinated fibres 
which are connected to the vagus nerve and to sympathetic ganglia. The sub-
mucous plexus (Meissner plexus) is located more superficially and closer to the 
intestinal lumen. It is mainly composed by nerve fibres and ganglia which control 
the mucous secretions, vascular flow and absorption [38]. The vagus nerve allows 
the direct connection between the intestine and the brain. By controlling motil-
ity and intestinal secretion, the vagus nerve can alter the intestinal environment 
and the response to the enteric immunological system with direct consequence 
to the intestinal microbiota. On the other hand, the intestinal bacteria produce 
metabolites which can influence the CNS and enteric and affect the production 
of neurotransmitters, such as GABA, acetylcholine, and the serotonin precursor, 
tryptophan [39].
Intestinal microbiota composition is regulated by extrinsic factors, such as 
lifestyle, precocious exposure to microbiota and diet, and intrinsic factors, such as 
metabolism, genetic history and the host’s immunological and hormonal systems 
activity [40]. Intestinal dysbiosis can have an infinite amount of consequences for 
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the CNS. Microbes can stimulate the liberation of small molecules, like cytokines, 
and produce metabolites which work as neuromodulators, such as short-chain fatty 
acids (SCFAs), GABA and serotonin precursors [41–43].
One of the most studied extrinsic factors is diet, since it can alter the intes-
tinal microbiota. Epidemiological studies show a positive correlation between 
the increase in risk of cognitive decline and high ingestion of animal protein, 
refined sugar and foods with high content of saturated fats [44]. Patients with 
refractory epilepsy can benefit from a ketogenic diet, since it can influence the 
intestinal microbiota [39]. The commensal bacteria in the intestine degrade  
the dietary fibre and lead to the production of SCFA, which are beneficial to the 
brain [44].
SCFAs are important bacterial metabolites which can reduce the inflammatory 
response, promote CNS plasticity, and increase the hematoencephalic permeability 
[45]. An exacerbated inflammatory response in the hippocampus is associated 
with a diet rich in fructose, and can be a consequence of alterations in intestinal 
 bacteria [46].
Colonization with Akkermansia Mucinophilia e Parabacteroides bacterias offers 
protection against convulsions, altering the level of cerebral neurotransmitters in 
the hippocampus, including GABA and glutamate. Intestinal microbiome dysbiosis 
can alter GABA, which is the main inhibitory neurotransmitter in the brain, and 
the reduced levels have been known to exacerbate convulsions [47–49]. But the 
reduction of Prevotellaceae and increase of Lactobacilliaceae are related to neuroin-
flammation and were discovered in neurodegenerative diseases such as Parkinson’s 
Disease [49]. An increase in Proteobacteria and Cronbacteria was found in patients 
with epilepsy [50]. Individuals with epileptic CP (CPE) exhibited lower proportions 
of Anaerostipes, Faecalibacterium e Bacteroides [51] which can produce butyrate 
with acetate [52] since butyrate can stimulate the differentiation of regulatory T 
cells (Treg) and relieve the neuroinflammation charge [53]. Nevertheless, great 
quantities of acetate would accumulate in these individuals, which could activate 
the parasympathetic nervous system [54] and unchain a convulsion. Besides that, 
the reduction of Bacteroids would also reduce butyrate secretion and attenuate its 
neuroprotector effect in patients with CPE [53]. On the other hand, a greater abun-
dance of Enterococcus, Bifidobacterium, Clostridium IV and Akkermansia were 
discovered in patients with CPE [51]. A deeper analysis of the microbial functions 
revealed an increased systemic immunological and neurodegenerative diseases in 
patients with CPE [51], and that neuroinflammation probably carried out a funda-
mental role in CPE pathology [55].
Dysbiosis and frequency of epileptic events are frequently correlated, suggest-
ing that the drugs can interact directly with the intestinal microbiota, modifying 
their metabolism and, therefore, affecting the efficacy and toxicity of the drugs 
[56]. Drugs are transformed into bioactive metabolites, inactive or toxic through 
direct microbial action or host-microbial co-metabolism. These metabolites are 
responsible for therapeutic effects or collateral effects induced by these medications 
[57]. Alteration in the microbiome can affect absorption and medicine metabolism, 
influencing their efficacy and resistance to the drug [58].
The antiepileptic medication is normally used in long-term clinical treat-
ment, and for this reason can cause serious collateral effects in the childhood 
development of patients with CP and epilepsy, such as: gastrointestinal complica-
tions including oral dysbiosis, gingival bleeding (GB) and increase in systemic 
 inflammation [35, 59].
CP’s inaccessibility and vulnerability to oral care and consequently the develop-
ment of caries and gingival diseases can also phenotypically affect the intestine 
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through the microbiome’s oral-intestine axis. These facts do not alone indicate 
alterations in the microbiome, but indicate that the gingival bleeding index suggests 
dysbiosis in the host-microbial interactions in the oral mucosa interface which then 
can influence an individual’s systemic inflammatory profile.
Current literature indicates that intestinal disturbances play a prominent role 
in inflammatory responses and neurological conditions [60]. This line of evidence 
is fundamental in identifying the effects of dysbiosis in mucosa inflammation in 
the entire digestive tract. Significantly higher levels of IL-1β, IL-6, IL-8 and IL-10 
were found in constipated individuals with GB (Figure 3), besides this, presence of 
chemokine IL-8 induces the secretion of lymphocytes, monocytes, epithelial cells, 
fibroblasts, tumor cells, bone reabsorption and IL-1β [61, 62], indicating a continu-
ous inflammatory process and progression of the periodontal disease [61–64]. The 
use of this medication caused individuals with CP to present reduced salivary flow, 
increase in the salivary osmolarity, dry mouth and gingivitis, which is represented 
by elevated levels of inflammatory cytokines in tetraplegics [59].
There is an elevated risk of immunological system diseases in these vulner-
able individuals, and oral and intestinal dysbiosis is attributed to an exacerbated 
increase of Akkermansia in patients with CPE [51]. The excessive increase in 
Akkermansia would degrade the mucin in the mucous layers and would increase the 
mucous permeability [65], which allows for more bacterial antigens to be exposed 
to the host’s immunological system, unchaining systemic immune reactions in 
individuals with CPE.
Figure 3. 
Constipation actions on Inflammatory Cytokine Levels. Distributions of each measured cytokine—(A) TNFα, 
(B) IL1β, (C) IL6, (D) IL8, and (E) IL10— in constipated subjects (blue) and non-constipated subjects 
(green) are mapped using a violin plot. White dots mark the means, bars show the inner quartiles, and 
whiskers mark the 5% confidence interval.
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5. Correlation between covid-19, brain injury and neuroinflammation
Vulnerable children are those with neurological diseases and lung problems, 
requiring respiratory care [66]. This situation is currently a priority with the advent 
of the new coronavirus disease of 2019 (COVID-19). This is a zoonotic virus, an 
enveloped RNA, which can be transmitted from a sick person to another by close 
contact through touch, handshake, droplets of saliva, sneeze, cough, phlegm and 
contaminated objects or surfaces [67, 68].
It was first detected in December 2019 and became an epidemic in Wuhan, 
Hubei province, China and quickly spread to several countries on six continents 
[69]. On March 11, 2020, the World Health Organization announced that COVID-
19 was characterized as a pandemic, threatening global public health and creating 
a record economic burden. Coronaviruses are a large family of viruses that cause 
diseases such as the common cold to more serious diseases, such as Severe Acute 
Respiratory Syndrome (SARS). A new coronavirus is typically a new strain of infec-
tious disease that has not been previously identified in humans [70].
The new 2019 coronavirus, coronavirus 2 of the severe acute respiratory syn-
drome (SARS-CoV-2) appeared after six other human coronaviruses. Four common 
human coronaviruses which cause light to moderate illness of the superior respira-
tory tract, including 229E (coronavirus alpha), NL63 (alpha coronavirus), OC43 
(beta coronavirus) and HKU1 (beta coronavirus), were registered for the first 
time in the 60’s [71]. Two other human coronaviruses are SARS-CoV and MERS-
CoV, which cause grave infections to pulmonary lesions, known as Severe Acute 
Respiratory Sickness (SARS-C0V) and Middle East Respiratory Syndrome (MERS-
CoV), respectively. The MERS-CoV outbreak occurred in 2012, starting in Saudi 
Arabia and spreading to other countries with a mortality rate of 37% [71, 72].
These are the diagnostic criteria [73]:
1. Asymptomatic Infection: without symptoms and clinical signs and normal 
thorax image, while the 2019 nCoV nucleic acid test is in a positive period.
2. Light: Acute symptoms of infection of the superior respiratory tract, including 
fever, fatigue, myalgia, cough, sore throat, coryza and sneezing. The physical 
exam shows pharyngeal congestion and absence of auscultatory abnormali-
ties. Some cases may not have fever or only present digestive symptoms such as 
nausea, vomit, abdominal pain and diarrhea.
3. Moderate: with pneumonia, fever and frequent coughs, especially dry cough, 
followed by productive cough, some may have a chest wheezing, but no obvi-
ous hipoxemia, with lack of air or dry wheezing and or wet wheezing. Some 
cases may not have signs or clinical symptoms but the Computerized Tomogra-
phy of the thorax shows subclinical pulmonary lesions.
4. Serious: precocious respiratory symptoms, such as fever and cough, can be 
followed by gastrointestinal symptoms, such as diarrhea. The disease gener-
ally progresses for about one week and dyspnoea occurs, with central cyanosis. 
Oxygen saturation is inferior to 92%, with other manifestations of hypoxia
5. Critical: Children can rapidly progress to acute respiratory distress symptom or 
respiratory insufficiency and can also present shock, encephalopathy, myo-
cardial or cardiac injury, coagulation dysfunction, and acute renal lesion. The 
organic dysfunction can be fatal.
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The majority of discussions based on evidence demonstrate the power of 
privilege during a pandemic, where it is indicated that the most vulnerable, such as 
seniors, people with deficiencies and aborigenes, will be the most impacted [74].
Children of all ages are sensitive to Covid-19, and there is no significant dif-
ference between the sexes. The clinical manifestations of cases of children with 
Covid-19 were less serious than those of adult patients. Nevertheless, small chil-
dren, especially babies, are also vulnerable to infection by Covid-19 [75]. Many 
families have to live in just one room with shared bathrooms and kitchen, causing 
overcrowding and making self isolation impossible in confined spaces. Many times, 
the children have inadequate space to crawl or play, and no access to fresh air. The 
duration of the outbreak is not clear and these children are more vulnerable both 
to the primary as well as the secondary effects, it is absolutely vital that they are no 
longer marginalized [76].
Antiviral immunity includes innate and adaptive immune responses. There 
are different innate immune receptors, the Toll like receptors (TLRs) are more 
intimately related to adaptive immune responses, therefore the TLRs are important 
antiviral immunity elements [77]. After a virus is recognized, the TLR signaling 
positively regulates the expression of pro-inflammatory cytokines and co-stimula-
tory molecules, through the accumulation of interferons (IFNs). Consequently, the 
adaptive antimicrobial immunity is processed by co-stimulatory molecules [78].
Patients with serious SARS-CoV infection show an aberration of the innate 
immune system. Particularly, the induction of proinflammatory cytokines, IFNs 
type I and genes stimulated by interferon (ISG) would suffer oscillations clearly 
favorable to SARS-CoV. The liberation of cytokines and pro-inflammatory chemo-
kines occurs on the first day of infection. High levels of proinflammatory cytokines 
in patients with SARS-CoV are correlated to symptoms of respiratory discomfort in 
old animals. The IFNs can help to control the replication of SARS-CoV. Therefore, 
it is possible to suppose that other innate immunological mechanisms will have an 
essential role in immunity against SARS-CoV [79].
A certain subgroup of the population of T cells develops a cytokine storm during 
initial stages of the SARS-CoV-2, involving cytokines and chemokines from the 
beginning until the other phases of the illness. In its initiation phase, SARS-CoV-2 
would increase the plasma concentration of different cytokines, including IL-1β, 
IL-1Rα, IL-7, IL-8, IL-9, IL-10, basic FGF G CSF, GMCSF, IFNγ, IP10, MCP1, 
MIP1A, MIP1B, PDGF, TNF-α and endothelial vascular growth factor. Critical 
patients interned in intensive care units (ICUs) presented higher levels of IL2, IL7, 
IL10, GCSF, IP10, MCP1, MIP1A and TNFα compared to those who did not need 
to be in the ICU. In SARS-CoV-2, there appears to be an interaction between dif-
ferent subsets of the population of T-helper cells (Th), for example, Th1, Th2 and 
Treg [80].
Both winter and low humidity act as stressors for the immune system. Evidence 
shows an association between cold temperatures and low humidity with respiratory 
tract infections whereby the lower the temperature/humidity, the greater the infec-
tions in the respiratory tracts of the population [81].
Precocious induction of interferon-gamma (IFN-γ) in viral infections, indicates 
a battle between innate immunity and the virus, so the immune system would start 
with a fever, to allow the expression of TLR4, and would unchain a series of antivi-
ral immune responses characterized by the production of cytokines. In almost 99% 
of cases, the most common initial symptom of SARS-CoV-2 is fever [82].
Evidence points to the effect of this new coronavirus in inhibiting antiviral 
immune responses and, therefore, its powerful capacity to replicate in the host 
cells. On the other hand, SARS-CoV-2 demonstrated a greater rate of incidence of 
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mortality in the senior population and in people with certain comorbidities which 
are known since they have differences in their immune profile [83].
Comorbidity is present in more than 30% of cases of infection with SARS-CoV-2 
[80]. Organized by related mortality rates, the chronic conditions in victims with 
the virus include cardiovascular diseases, diabetes, chronic respiratory diseases, 
hypertension and cancer. All of these conditions, in the long run, tend to make 
the immune system imperfect, both in innate and adaptive terms in the immune 
 functions [84].
Brain injury caused by hypoxia increases the risk of developing epilepsy that 
is difficult to control. In the presence of infection by SARS-CoV-2, there is greater 
susceptibility to the occurrence of convulsions, increasing their vulnerability.
6. Conclusion
Dysbiosis causes an increase in mucous permeability (leaky-gut) of the gut-
brain axis, and increase in serum endotoxin, demonstrating a persistent inflamma-
tory state, and supporting the emergence of new side effects, which can become the 
object of future research.
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